Don't know if many remember this PR from Mar of th
Post# of 72433
![](/assets/46931549/no_avatar_available_thumb.jpg)
Anyone have any idea how long a P1 on healthy candidates should take when only criteria seems to be how well trial members tolerate the oral form of K and the safety of oral K in regards to these studies: photosafety testing, pharmacokinetics, in vivo metabolism, metabolic stability, protein binding, and genetic and physiological toxicology reports?
Have no idea how this work on oral K could be used for oral P but I am sure company is learning a lot which should benefit us all down the line in bringing about an oral P as soon as possible.
http://www.ipharminc.com/press-release/2017/3...ncer-agent
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)